|
1
|
Chen W, Delongchamps NB, Mao K, Beuvon F,
Peyromaure M, Liu Z and Dinh-Xuan AT: High RhoA expression at the
tumor front in clinically localized prostate cancer and association
with poor tumor differentiation. Oncol Lett. 11:1375–1381. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ryu CJ, Whitehurst CE and Chen J:
Expression of Gal4-VP16 and Gal4-DNA binding domain under the
control of the T lymphocyte-specific lck proximal promoter in
transgenic mice. BMB Rep. 41:575–580. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamashita Y: Ovarian cancer: New
developments in clear cell carcinoma and hopes for targeted
therapy. Jpn J Clin Oncol. 45:405–407. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Song Y, Xin X, Zhai X, Xia Z and Shen K:
Sequential combination therapy with flavopiridol and autocatalytic
caspase-3 driven by amplified hTERT promoter synergistically
suppresses human ovarian carcinoma growth in vitro and in mice. J
Ovarian Res. 7:1212014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi
H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, et al: A novel hTERT
promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer
Ther. 8:2375–2382. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu L, Johnson M and Sato M:
Transcriptionally targeted gene therapy to detect and treat cancer.
Trends Mol Med. 9:421–429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin J, Zeng D, He H, Tan G, Lan Y, Jiang F
and Sheng S: Gene therapy for human ovarian cancer cells using
efficient expression of Fas gene combined with γδ T cells. Mol Med
Rep. 16:3791–3798. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Song Y, Xin X, Xia Z, Zhai X and Shen K:
Selective suppression of autocatalytic caspase-3 driven by two-step
transcriptional amplified human telomerase reverse transcriptase
promoter on ovarian carcinoma growth in vitro and in mice. Oncol
Rep. 32:225–234. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun R, Lin SF, Gradoville L, Yuan Y, Zhu F
and Miller G: A viral gene that activates lytic cycle expression of
Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA.
95:10866–10871. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iyer M, Salazar FB, Lewis X, Zhang L, Wu
L, Carey M and Gambhir SS: Non-invasive imaging of a transgenic
mouse model using a prostate-specific two-step transcriptional
amplification strategy. Transgenic Res. 14:47–55. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nakamura M, Nagano H, Sakon M, Yamamoto T,
Ota H, Wada H, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, et
al: Role of the Fas/FasL pathway in combination therapy with
interferon-alpha and fluorouracil against hepatocellular carcinoma
in vitro. J Hepatol. 46:77–88. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guillermo LV, Silva EM, Ribeiro-Gomes FL,
De Meis J, Pereira WF, Yagita H, DosReis GA and Lopes MF: The Fas
death pathway controls coordinated expansions of type 1 CD8 and
type 2 CD4 T cells in Trypanosoma cruzi infection. J Leukoc Biol.
81:942–951. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brenes O, Arce F, Gätjens-Boniche O and
Díaz C: Characterization of cell death events induced by
anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on
human hepatoma cell lines: Possible mechanisms of cell resistance.
Biomed Pharmacoth. 61:347–355. 2007. View Article : Google Scholar
|
|
14
|
Collins M and Thrasher A: Gene therapy:
Progress and predictions. Proc Biol Sci. 282:201430032015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Naldini L: Gene therapy returns to centre
stage. Nature. 526:351–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang D and Gao G: State-of-the-art human
gene therapy: Part II. Gene therapy strategies and clinical
applications. Discov Med. 18:151–161. 2014.PubMed/NCBI
|
|
17
|
Hoshida H, Murakami N, Suzuki A, Tamura R,
Asakawa J, Abdel-Banat BM, Nonklang S, Nakamura M and Akada R:
Non-homologous end joining-mediated functional marker selection for
DNA cloning in the yeast Kluyveromyces marxianus. Yeast. 31:29–46.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mitsiades N, Yu WH, Poulaki V, Tsokos M
and Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of
Fas ligand protects tumor cells from chemotherapeutic drug
cytotoxicity. Cancer Res. 61:577–581. 2001.PubMed/NCBI
|
|
19
|
Villa-Morales M and Fernández-Piqueras J:
Targeting the Fas/FasL signaling pathway in cancer therapy. Expert
Opin Ther Targets. 16:85–101. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu HL, Wang YZ, Yu L, Li B, Yao SQ and
Lou FD: The expression of Fas, FasL and Bcl-2 on RMA cells during
the process of apoptosis induced by chemotherapeutic drugs.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 10:35–39. 2002.(In Chinese).
PubMed/NCBI
|
|
21
|
Lin T, Gu J, Zhang L, Huang X, Stephens
LC, Curley SA and Fang B: Targeted expression of green fluorescent
protein/tumor necrosis factor-related apoptosis-inducing ligand
fusion protein from human telomerase reverse transcriptase promoter
elicits antitumor activity without toxic effects on primary human
hepatocytes. Cancer Res. 62:3620–3625. 2002.PubMed/NCBI
|
|
22
|
Zhang Y, Ma H, Zhang J, Liu S, Liu Y and
Zheng D: AAV-mediated TRAIL gene expression driven by hTERT
promoter suppressed human hepatocellular carcinoma growth in mice.
Life Sci. 82:1154–1161. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Iyer M, Wu L, Carey M, Wang Y, Smallwood A
and Gambhir SS: Two-step transcriptional amplification as a method
for imaging reporter gene expression using weak promoters. Proc
Natl Acad Sci USA. 98:14595–14600. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Watanabe M, Ueki H, Ochiai K, Huang P,
Kobayashi Y, Nasu Y, Sasaki K, Kaku H, Kashiwakura Y and Kumon H:
Advanced two-step transcriptional amplification as a novel method
for cancer-specific gene expression and imaging. Oncol Rep.
26:769–775. 2011.PubMed/NCBI
|
|
25
|
Merritt RE, Mahtabifard A, Yamada RE,
Crystal RG and Korst RJ: Cisplatin augments cytotoxic
T-lymphocyte-mediated antitumor immunity in poorly immunogenic
murine lung cancer. J Thorac Cardiovasc Surg. 126:1609–1617. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park IJ, Kim MJ, Park OJ, Park MG, Choe W,
Kang I, Kim SS and Ha J: Cryptotanshinone sensitizes DU145 prostate
cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and
MAPK regulation. Cancer Lett. 298:88–98. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanagawa N, Yanagawa T, Nakagawa T, Okada
N and Nakagawa S: Tumor vessel-injuring ability improves antitumor
effect of cytotoxic T lymphocytes in adoptive immunotherapy. Cancer
Gene Ther. 20:57–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Habib HM, Taher TE, Isenberg DA and Mageed
RA: Enhanced propensity of T lymphocytes in patients with systemic
lupus erythematosus to apoptosis in the presence of tumour necrosis
factor alpha. Scand J Rheumatol. 38:112–120. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Xie J, Xiong L, Tao X, Li X, Su Y, Hou X
and Shi H: Antitumor effects of murine bone marrow-derived
dendritic cells infected with xenogeneic livin alpha recombinant
adenoviral vectors against Lewis lung carcinoma. Lung cancer.
68:338–345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Matthews KS, Alvarez RD and Curiel DT:
Advancements in adenoviral based virotherapy for ovarian cancer.
Adv Drug Deliv Rev. 61:836–841. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mahasreshti PJ, Kataram M, Wu H,
Yalavarthy LP, Carey D, Fisher PB, Chada S, Alvarez RD, Haisma HJ,
Dent P and Curiel DT: Ovarian cancer targeted adenoviral-mediated
mda-7/IL-24 gene therapy. Gynecol Oncol. 100:521–532. 2006.
View Article : Google Scholar : PubMed/NCBI
|
